NasoVAX (intranasal flu vaccine) / Altimmune  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NasoVAX (intranasal flu vaccine) / Altimmune
NCT03232567: Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Completed
2
60
US
NasoVAX
Altimmune, Inc.
Influenza
03/18
06/18
NCT04442230: NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Terminated
2
48
US
NasoVAX, Placebo
Altimmune, Inc.
Coronavirus Infection
02/21
02/21

Download Options